|
GB0012923D0
|
|
Schizophrenia related genes
|
|
GB0007880D0
|
|
Schizophrenia related genes
|
|
AU3074000A
|
|
Compositions containing highly purified heparin cofactor ii and method for separating the same
|
|
AU1416100A
|
|
Heparin cofactor ii-containing compositions and process for producing the same
|
|
CN1332726A
|
|
Pyrrolidine compounds and medicinal utilizaion thereof
|
|
JP2000086603A
|
|
Cinnamic acid amide derivative and 3-phenylpropionic acid amide derivative
|
|
WO0002534A1
|
|
Kit of drug-containing preparation to be prepared before using and resolvent therefor
|
|
AU4397599A
|
|
Medicinal utilization of heparin cofactor ii
|
|
JP2000038350A
|
|
Diabetes therapeutic drug
|
|
JPH11343229A
|
|
Solution containing stabilized fat emulsion
|
|
WO9945953A1
|
|
Heparin cofactor ii-containing compositions and method for stabilizing the same
|
|
WO9940063A1
|
|
Novel azapeptide type hydroxamic acid derivatives
|
|
AU1983699A
|
|
Method for measuring heparin cofactor ii activity and reagent kit
|
|
JPH11292722A
|
|
Method and apparatus for sterilization using vapor of isothiocyanic acid ester
|
|
JPH11349490A
|
|
Albumin preparation
|
|
AU1684999A
|
|
Chymase inhibitors
|
|
JP2000169468A
|
|
3,4-dihydro-2h-1,5-benzodioxepin compound
|
|
JP2000169394A
|
|
Apoptosis revulsive
|
|
WO9926925A1
|
|
Tryptase inhibitors comprising heterocyclic amide compounds
|
|
AU1175099A
|
|
Agent for prophylaxis and treatment of panic disorder
|
